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Objective: To comprehensively describe the identification, refinement, and selection of 
attributes and levels for a discrete choice experiment (DCE) on preferences of patients with 
rheumatoid arthritis (RA) regarding disease-modifying antirheumatic drugs (DMARDs).
Methods: A mixed-methods approach, consisting of three consecutive steps: a literature review, 
expert recommendations, and focus groups. Attributes and levels were identified by a scoping 
review and compiled into a list that was evaluated on its relevance by an expert panel. The list 
that resulted thereafter was used to inform three focus groups, including 23 patients with RA. 
New attributes and levels could be identified during the focus groups. Also, a ranking exercise 
was performed. The patients individually ranked the attributes (ie, the ones on the list and newly 
identified attributes) by relevance. The patients’ individual rankings were summed to derive a 
ranking at group level and make an a priori selection of the most relevant attributes. The group 
discussions were transcribed for qualitative analysis.
Results: Nineteen attributes, each specified by two to seven levels, were identified by the scop-
ing review. The expert recommendations resulted in the removal of one attribute. Furthermore, 
two new attributes and levels were identified and two attributes were split into two. One new 
attribute was identified during the focus groups. The results of the ranking exercise and qualitative 
analysis led to the refinement and selection of the following attributes: route of administration, 
frequency of administration, chance of efficacy, onset of action, risk of serious infections, risk 
of liver injury, and risk of cancer. Each attribute was specified by three levels.
Conclusion: This study contributes to the limited literature on the development of attributes 
and levels. Future research should pay more attention to a comprehensive description of this 
process. It ensures transparency and thereby allows researchers to judge a DCE’s quality and 
generalizability.
Keywords: discrete choice experiment, mixed-methods, patient preferences, rheumatoid 
arthritis, disease-modifying antirheumatic drugs
Introduction
Treatment of rheumatoid arthritis (RA) rests primarily on the long-term use of 
disease-modifying antirheumatic drugs (DMARDs). It is recommended to start 
DMARD therapy as soon as possible after the diagnosis is confirmed.1,2 Early initia-
tion enables optimal control of disease progression, reduces radiological damage and 
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improves patients’ functioning and prognosis.3 However, the 
full benefits of DMARDs are often not realized because many 
patients are non-adherent (ie, they do not take their medica-
tion as prescribed). Empirical studies showed adherence rates 
varying from 30% to 80%.4 Non-adherence contributes to 
poor clinical outcomes and increased healthcare utilization 
and costs.5 Patient preferences play an important role in 
adherence. Patients are more likely to be satisfied with and 
adhere to a treatment that is in line with their preferences.4,6 
Therefore, along with clinical guidelines, preferences of 
patients with RA should provide direction in making choices 
regarding DMARD therapy.1,2
Discrete choice experiments (DCEs) are increasingly 
used to elicit patient preferences.7 They are based on the 
assumption that a treatment can be described by its charac-
teristics, also referred to as attributes (eg, for medication: 
route of administration). Attributes in turn are specified by 
several levels (eg, for route of administration: oral, subcuta-
neous and intravenous). DCEs are typically implemented in 
surveys consisting of a series of choice tasks.8–11 A choice task 
consists of two or more realistic, but hypothetical, treatments 
between which patients are asked to choose. Treatments are 
described by a number of attributes and each attribute takes 
one of several levels. Patients’ choices provide information 
on the relative importance of the attributes and the trade-offs 
that they are willing to make between them. Furthermore, the 
exact influence of each level on their choices can be quanti-
fied through statistical modeling.12
In recent years, several studies have used a DCE to elicit 
preferences of patients with RA regarding DMARDs.13–16 
These studies reported extremely briefly on the development 
of attributes and levels. They only described the methods that 
were used to identify attributes and levels (eg, a literature 
review, interviews, and focus groups). Detailed information 
about search strings, eligibility criteria, interview guides 
and so forth were lacking. The development of attributes 
and levels is, however, a fundamentally important process. 
The validity of a DCE largely depends on the researchers’ 
ability to specify relevant attributes and levels.8–10,17 Due to 
the brevity of reporting in previous research, it is unclear 
whether the development of attributes and levels is con-
ducted rigorously.18 A comprehensive description of this 
process ensures transparency and thereby allows research-
ers to judge a DCE’s quality and generalizability.18 It also 
provides a reference point for future studies. Therefore, 
the aim of this study was to comprehensively describe the 
identification, refinement, and selection of attributes and 
levels for a DCE on preferences of patients with RA regard-
ing DMARDs.
Methods
A variety of methods are being used to develop attributes and 
levels for a DCE, including a literature review, expert recommen-
dations, existing health outcome measures, surveys, interviews, 
and focus groups.17,18 The use of qualitative methods, before, 
alongside or after other methods, is highly recommended by 
experts in the field.8–10,18,19 Qualitative methods have the particular 
advantage of allowing researchers to draw on the views of future 
respondents. This minimizes the potential for misspecification 
of attributes and levels through overreliance on the researchers’ 
own views.18 In this study, a mixed-method approach was used. 
It consisted of three consecutive steps: 1) a literature review; 
2) expert recommendations; and 3) focus groups.
step 1: A literature review
A scoping review was performed to rapidly examine the extent, 
range and nature of research activity.20 The framework of Ark-
sey and O’Malley20 was followed. This framework provides a 
comprehensive foundation for scoping review methodology 
and comprises five stages: 1) identifying the research question; 
2) identifying relevant studies; 3) study selection; 4) charting the 
data; and 5) collating, summarizing and reporting the results.20
identifying the research question 
The following research question was identified: What 
attributes and levels of DMARDs, used to treat RA, can be 
identified from the literature?
identifying relevant studies
The databases of PubMed, Embase and CINAHL were 
searched from inception to October 2016, using both Medical 
Subject Headings (MeSH) terms and free text words. There 
were no restrictions on study designs. Only publications 
written in English were included. Table 1 shows the search 
strings that were used.
study selection
After combining the search results from the three databases, 
duplicates were removed. The remaining publications were 
screened for inclusion on two levels. The first level concerned a 
screening on title and abstract and the second level a screening of 
the full texts. The inclusion criteria were: 1) studies on adult (ie, 
aged 18 years or older) patients with RA; and 2) studies on attri-
butes of DMARDs, preferences for DMARDs or experiences 
with DMARDs. Two researchers (EM and MV) independently 
screened the publications on title and abstract. The full texts of 
the publications that met the inclusion criteria were obtained and 
independently screened by the same researchers. The publica-
tions were excluded if they did not meet the inclusion criteria. 
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In case of disagreement a third researcher (LvD) was decisive 
in including or excluding the publications.
Charting the data and collating, summarizing and 
reporting the results
For each of the included publications data were charted: 
author(s) (year of publication), objective(s), study design, 
study population and sample size, attributes (levels), and 
conclusion. This was done by three researchers (EM, MV 
and MvH). Each researcher charted a part of the data. Based 
on the data chart, attributes and levels were identified and 
the researchers jointly compiled a list.
step 2: expert recommendations
The list of attributes and levels was evaluated by an expert 
panel. A purposive sampling approach was used to recruit 
two rheumatologists, two pharmacists, two rheumatology 
nurses or nurse practitioners, two researchers, and two 
patients with RA. The experts were not in any other way 
involved in this study. The list was sent to them by email and 
provided with a brief instruction. The experts were instructed 
to independently comment on the relevance of the attributes 
and levels. Also, they were encouraged to add new attributes 
and levels to the list. Their recommendations were processed 
by the researchers. This resulted in a more comprehensive 
list that was used to inform the focus groups.
step 3: Focus groups
Patient recruitment
Patients were recruited from the outpatient pharmacy of the 
Sint Maartenskliniek in Nijmegen, the Netherlands and the 
local rheumatology patient association in ‘s-Hertogenbosch, 
the Netherlands. A convenience sampling approach was used. 
Eligibility criteria were: 1) a diagnosis of RA, confirmed by a 
rheumatologist; 2) aged 18 years or older; and 3) proficiency 
in the Dutch language. An invitation letter and informed 
consent form were sent to eligible patients. Personal experi-
ences of the researchers with this recruitment technique (ie, 
impersonal invitations for focus groups on predetermined 
dates and times) showed response rates of 5%–10%. There-
fore, a group of 400 patients was invited.
Data collection
The focus groups were facilitated by an independent, expe-
rienced moderator (AH) and an assistant moderator (EM). A 
discussion guide, including engagement, exploratory and exit 
questions, was used to standardize and structure the data col-
lection (Figure S1).21 All focus groups were audio recorded and 
subsequently transcribed verbatim by a professional transcription 
service. Before the start of the focus groups, each patient com-
pleted a brief questionnaire on socio-demographic and clinical 
characteristics, including age, gender, educational level, employ-
ment status, disease duration, and current DMARD use.
The focus groups were divided into two parts. First, the 
patients individually wrote down attributes and levels of 
DMARDs that were important to them in making choices 
regarding DMARD therapy. This was followed by a group 
discussion. Second, a ranking exercise was performed to 
scale down the number of attributes to a number manageable 
within a DCE. There is no consensus in the literature on what 
counts as a manageable number. Reviews showed that, in 
practice, most DCEs included a number of attributes between 
Table 1 search strings
PubMed CINAHL Embase
(rheumatoid arthritis [Mesh] Or 
rheumatoid arthritis)
AnD
(Antirheumatic agents [Mesh] Or 
Antirheumatic agents Or DMArDs Or 
DMArD Or Azathioprine Or Methotrexate 
Or sulfasalazine Or hydroxychloroquine 
OR Auranofin OR Leflunomide OR 
etanercept Or Adalimumab Or golimumab 
OR Infliximab OR Certolizumab OR 
Abatacept Or Tocilizumab Or rituximab)
AnD
(preferences Or attributes Or experiences)
(MH “Arthritis, Rheumatoid+” Or 
rheumatoid arthritis)
AnD
(Mh “Antirheumatic Agents+” Or 
antirheumatic agents Or DMArDs Or 
DMArD Or Azathioprine Or Methotrexate 
Or sulfasalazine Or hydroxychloroquine 
OR Auranofin OR Leflunomide OR 
etanercept Or Adalimumab Or golimumab 
OR Infliximab OR Certolizumab OR 
Abatacept Or Tocilizumab Or rituximab)
AnD
(preferences Or attributes Or experiences)
exp rheumatoid arthritis/ Or rheumatoid 
arthritis.mp.
AnD
exp Antirheumatic agent/ Or Antirheumatic 
agents.mp. Or DMArDs.mp. Or 
DMArD.mp. Or Methotrexate.mp. Or 
Azathioprine.mp. Or sulfasalazine.mp. Or 
Hydroxychloroquine.mp. OR Auranofin.mp. 
OR Leflunomide.mp. OR Etanercept.mp. OR 
Adalimumab.mp. Or golimumab.mp. Or 
Infliximab.mp. OR Certolizumab.mp.  
Or Abatacept.mp. Or Tocilizumab.mp. 
Or rituximab.mp.
AnD
preferences.mp. Or attributes.mp.  
Or experiences.mp.
Abbreviations: DMARD, disease-modifying antirheumatic drug; MeSH, Medical Subject Headings.
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four and seven.11,22 The list of attributes and levels derived 
from the literature review and expert recommendations was 
presented to the patients. They were asked to individually 
rank the attributes by relevance. Rank one represented the 
most relevant attribute. Attributes that were newly identified 
during the first part of the focus group could also be ranked. 
A group discussion on the patients’ individual rankings and the 
wording of the attributes and levels was held afterwards.
Data analysis
The patients’ individual rankings were summed to derive a 
ranking at group level and make an a priori selection of the 
most relevant attributes. The transcripts were analyzed using 
a thematic analysis method.23 This was done independently 
by two researchers (MvH and SZ). Both a deductive and 
inductive approach were used. The codes and themes were 
pre-selected based on the list of attributes and levels. The 
inductive approach led to a revision of the pre-selected codes 
and themes. Additionally, new ones were identified. The 
inductive approach also made it possible for the researchers 
to gain a deeper insight into the relevance of the attributes 
and levels from the view of patients with RA. The software 
program MAXQDA 10 was used for the qualitative analysis. 
It was checked whether data saturation occurred. This was 
defined as the point where no new codes and themes were 
identified.24 Also, a member check was performed. A sum-
mary of the discussions was sent to the patients by email and 
they were asked to comment on its accuracy. Eventually, the 
results of the ranking exercise and qualitative analysis were 
extensively discussed by the researchers and decisions on 
the selection of attributes and levels in the DCE were jointly 
made. Two rheumatologists, who were not involved in the 
expert panel, were consulted for recommendations regarding 
the range of the levels.
Pilot test
A series of choice tasks for the DCE were composed, using 
the selected attributes and levels. The choice tasks were 
implemented in a survey. Eleven patients with RA were 
invited to complete the survey. They were members of a local 
panel for patient participation in research. An invitation was 
sent to them by email and included a link to the survey. Also, 
a corresponding, open-ended questionnaire was attached 
(Box S1). Their understanding of the attributes and levels 
was reviewed. They were also asked to comment on the 
wording of the attributes and levels. Next to that, the pilot 
test reviewed the acceptability of the number of attributes 
and levels and total length of the survey.
ethical considerations
The medical research ethical committee (MREC) of Arnhem-
Nijmegen, the Netherlands, waived ethical approval since 
the study was not subject to the medical research involving 
human subjects act (file number: 2016–2474). All patients 
signed informed consent for participation in the focus groups. 
Patient data were handled according to the applicable laws 
and regulations. Personal identifying information was 
replaced by study codes. A document that linked the study 
codes to the patients’ identifying information was digitally 
stored and protected.
Results
This study’s mixed-methods approach consisted of three 
consecutive steps. In order to portray the whole process, the 
results are described step by step.
step 1: A literature review
The search generated 884 publications (PubMed: n=262; 
Embase: n=481; and CINAHL: n=141). After removing 
duplicates (n=232), 652 publications remained. The first-
level screening on title and abstract led to the exclusion of 611 
publications. Twenty-eight more publications were excluded 
after the second-level screening of the full texts: 14 publica-
tions were conference abstracts, 11 publications did not meet 
the inclusion criteria, two publications were not written in 
English and one publication turned out to be a previously 
overlooked duplicate. In total, 13 publications, representing 
13 unique studies, were included.13–15,25–34 Figure 1 shows the 
flowchart of the selection process.
Data were charted for each of the included publications 
(Table S1). Based on the data chart, 19 attributes were iden-
tified. Each attribute was specified by two to seven levels. 
Table 2 shows the list of attributes and levels that resulted 
after the literature review.
step 2: expert recommendations
The evaluation of the experts resulted in the removal of one 
attribute (improvement in daily functioning). This attribute 
was specified by the levels “45% of the patients feel much 
better”, “60% of the patients feel much better”, and “75% of 
the patients feel much better”. It was considered not specific 
enough and therefore likely to give rise to ambiguities. Two 
new attributes were identified: “required storage conditions” 
and “chance of injection side reaction”. Regarding the 
attribute “frequency of administration” one new level (once 
every 12 weeks) was identified. One new level (at the general 
practice) was also identified regarding the attribute “location 
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of administration”. Furthermore, the scope of two attributes 
“experience with DMARD” and “risk of dizziness, nausea, 
vomiting or diarrhea” was considered too broad. These 
attributes were split into two. The first was split into “years 
of experience with DMARD to treat RA” and “knowledge 
about long-term consequences of DMARD use” and the 
second was split into “risk of headache or dizziness” and 
“risk of gastrointestinal complications”. The result after the 
expert recommendations was a more comprehensive list of 
22 attributes, each specified by two to eight levels.
step 3: Focus groups
Three focus groups including 23 patients with RA were con-
ducted. The focus groups lasted between 90 and 120 minutes. 
Table 3 shows the socio-demographic and clinical charac-
teristics of the patients.
Identification
The patients in the first and second focus group did not iden-
tify new attributes and levels. One new attribute (contrain-
dicated during pregnancy and breast feeding) was identified 
during the third focus group. This attribute was also ranked. 
The highest ranked, and thus most relevant attributes at 
group level, were: 1) risk of cancer; 2) risk of liver injury; 
3) chance of efficacy; 4) risk of joint damage; 5) onset of 
action; 6) risk of serious infections; and 7) knowledge about 
long-term consequences of DMARD use. “Costs” was the 
lowest ranked attribute. Table S2 includes the patients’ rank-
ing. The group discussions mainly focused on the relevance 
of the attributes “route of administration” and “frequency of 
administration”. Also, the patients expressed their prefer-
ences for DMARDs with a low risk of side effects. Adjust-
ments to the wording of the attributes and levels were not 
deemed necessary.
Refinement and selection
Based on the literature, the researchers decided to include 
seven attributes in the DCE.11,22 The refinement and selection 
of the attributes and levels required some difficult decisions. 
The attributes “route of administration” and “frequency of 
administration” were not highly ranked. The results of the 
qualitative analysis, however, revealed that these attributes 
were relevant from the view of patients with RA. Indeed, the 
group discussions mainly focused on their relevance. It was 
therefore decided to include them anyway. The attributes 
“risk of joint damage” and “knowledge about long-term 
consequences of DMARD use” were highly ranked. Yet, 
it was decided not to include these attributes. The first was 
Figure 1 Flowchart selection process.
6HDUFKLQ3XE0HG1 
)LUVWOHYHOVFUHHQLQJIRULQFOXVLRQQ 
6HFRQGOHYHOVFUHHQLQJIRULQFOXVLRQQ 
6HDUFKLQ&,1$+/1 
3XEOLFDWLRQVLQFOXGHGQ 
6HDUFKLQ(PEDVH1 
5HPRYDORIGXSOLFDWHVQ 
6FUHHQLQJRQWLWOHDQGDEVWUDFWSXEOLFDWLRQVH[FOXGHG
6FUHHQLQJRIWKHIXOOWH[WVSXEOLFDWLRQVH[FOXGHG
5HDVRQVIRUH[FOXVLRQ&RQIHUHQFHDEVWUDFWQ 'LGQRWPHHWWKHLQFOXVLRQFULWHULDQ 1RWZULWWHQLQ(QJOLVKQ 'XSOLFDWH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considered to be dependent on the attribute “chance of 
efficacy”. The second was considered not specific enough 
since it was unclear how many years were meant by long-
term. The researchers acted upon the consulted rheumatolo-
gists’ recommendations to include realistic levels. On the one 
hand, the range of levels had to be wide enough to induce 
trading behavior. On the other hand, however, levels had to be 
realistic in order to obtain clinically meaningful results.7
The results of the ranking exercise and qualitative 
analysis led to the refinement and selection of the following 
attributes: 1) route of administration; 2) frequency of admin-
istration; 3) chance of efficacy; 4) onset of action; 5) risk of 
serious infections; 6) risk of liver injury; and 7) risk of cancer. 
Each attribute was specified by three levels. Table 4 shows 
the attributes and levels that were eventually included in the 
DCE. Quotes from the transcripts of the focus groups were 
included in Table 4 to prove that decisions on the inclusion 
of attributes and levels were rooted in the patients’ voices.
Pilot test
The survey and corresponding questionnaire were com-
pleted by five patients with RA. They had no difficulties in 
understanding the attributes and levels. The wording of the 
attributes and levels was also considered appropriate. The 
patients only noticed some minor typos that were corrected by 
the researchers. The pilot test revealed that both the number 
of attributes and total length of the survey were acceptable. 
All patients completed the survey in 15 to 20 minutes. Apart 
from the correction of typos, no adjustments were made to 
the attributes and levels.
Discussion
In contrast to previous studies, this study comprehensively 
described the identification, refinement, and selection of 
attributes and levels for a DCE on preferences of patients 
with RA regarding DMARDs. The attributes and levels 
were developed using a mixed-method approach, consist-
ing of three consecutive steps. A list of attributes and levels 
Table 2 list with attributes and levels
Attribute Levels
combination therapy Yes
no
route of administration Oral
subcutaneous
intravenous
location of administration At home
At the hospital
Preparation of DMArD needed Yes
no
Frequency of administration Daily
Twice a day
Weekly
every 2 weeks
every 4 weeks
every 8 weeks
every 6 months
Time needed for infusion 30 minutes
60 minutes
120 minutes
240 minutes
experience with DMArD More than 20 years of experience
new DMArD with unknown  
long-term consequences
Chance of efficacy 40%
60%
75%
Onset of action 1 week
2 weeks
4 weeks
6 weeks
8 weeks
improvement in daily functioning 45% of the patients feel much better
60% of the patients feel much better
75% of the patients feel much better
risk of joint damage 60% of the patients develops no joint 
damage within 1 year
75% of the patients develops no joint 
damage within 1 year
risk of cancer no increased risk
0.1% increased risk
risk of serious infections 1% increased risk
5% increased risk
risk of liver injury no increased risk
0.1% increased risk
1% increased risk
risk of hair loss no increased risk
10% increased risk
Risk of dizziness, nausea,  
vomiting or diarrhea
no increased risk
10% increased risk
30% increased risk
risk of mouth ulcers no increased risk
10% increased risk
risk of skin rash no increased risk
10% increased risk
40% increased risk
(Continued)
Table 2 (Continued)
Attribute Levels
costs 500–1,000 euros per patient  
per year
1,000–10,000 euros per patient  
per year
10,000–15,000 euros per patient 
per year
Abbreviation: DMARD, disease-modifying antirheumatic drug.
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Table 3 socio-demographic and clinical characteristics of the patients
Characteristic Group 1
(N=8)
Group 2
(N=11)
Group 3
(N=4)
Total
(N=23)
Age in years (median (range)) 57 (52–78) 62 (38–78) 62.5 (36–68) 62 (36–78)
gender (%)
Male 0 18 25 13
Female 100 82 75 87
educational levela (%)
low 38 73 0 48
Medium 25 27 50 30
high 38 0 50 22
employment status (%)
employed 50 18 0 26
Unemployed 50 82 100 74
Disease duration in years (median (range)) 7 (2–25) 8 (2–42) 16 (12–22) 11 (2–42)
current DMArD use (%)
sDMARD, methotrexate 50 27 75 44
sDMARD, otherb 38 36 0 30
bDMARD, anti-TNF 50 46 50 48
bDMARD, otherc 13 18 25 17
Notes: alevel of education: low = up to and including lower technical and vocational training; medium = up to and including secondary technical and vocational training; 
high = up to and including higher vocational training and university. bsDMARD, other: Hydroxychloroquine and Sulfasalazine. cbDMARD, other: Rituximab and Tocilizumab.
Abbreviations: DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor.
Table 4 included attributes and levels
Attribute Levels Quotes
route of administration Oral
subcutaneous
intravenous
•	 “I’d rather have pills than injections.” (Patient 103, female, 55 years)
•	 “They did offer to put me on the drip once, but I do not want that. I want to be 
in control myself. […] if i do the injections myself i still have the idea of being in 
control.” (Patient 203, female, 52 years)
Frequency of administration Daily
Weekly
Monthly
•	 “I would not want to be on the drip too often, as it takes up a lot of time.” 
(Patient 301, female, 36 years)
•	 “[…] and then you have to take all those stupid pills in between. They determine 
your day. I cannot really cope with that.” (Patient 202, female, 45 years)
•	 “Taking something on a daily basis would not be acceptable to me. Then you’re 
always busy with your medicines.” (Patient 207, female, 67 years)
Chance of efficacy 40%
60%
80%
•	 “Well, I think it is important that the medicine works for me. That’s the main 
thing.” (Patient 205, male, 60 years)
•	 “It should work. I do not want to be ill. Period.” (Patient 106, female, 62 years)
Onset of action 1 week
6 weeks
12 weeks
•	 “How long it takes for the medicine to work. As soon as possible, as far as I’m 
concerned.” (Patient 108, female, 73 years)
risk of serious infections no increased risk
0.5% increased risk
1% increased risk
•	 “i have used a biological for 3 months. But it didn’t work for me so i was 
allowed to stop using it. i was so frightened when i read about things like 
infections. Then i thought: oh no! Actually … i was happy when i could stop 
using it.” (Patient 303, female, 62 years)
risk of liver injury no increased risk
0.1% increased risk
1% increased risk
•	 “To me, my health is my greatest wealth. […], the risk of kidney or liver injury. 
[…] These are things that matter to me.” (Patient 203, female, 52 years)
risk of cancer no increased risk
0.1% increased risk
0.5% increased risk
•	 “What else do I find important? The risk of cancer. […] I am very frightened of 
that, cancer.” (Patient 211, female, 78 years)
was derived from the first two steps (ie, a literature review 
and expert recommendations) and used to inform the focus 
groups in the third step. Eventually, these steps resulted in the 
selection of seven attributes, each specified by three levels. 
A pilot test confirmed the appropriateness of the attributes 
and levels for inclusion in the DCE.
The following attributes were included: 1) route of 
administration; 2) frequency of administration; 3) chance 
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of efficacy; 4) onset of action; 5) risk of serious infections; 
6) risk of liver injury; and 7) risk of cancer. The attributes 
“route of administration” and “frequency of administration” 
were also included in all previous studies.13–16 This study 
confirmed that these attributes are highly relevant when con-
sidering attributes for inclusion in comparable DCEs. During 
the focus groups, preferences for DMARDs with a low risk 
of side effects were expressed by the patients. Comparable 
DCEs should therefore be considered to include attributes 
referring to side effects. Side effects differ in severity. It is 
important to realize that severity is a subjective term. What 
is severe to one person may not necessarily be severe to 
another. In order to avoid ambiguous interpretations one 
should not use such subjective terms (eg, risk of severe 
side effects). Whereas one previous study also included 
the attribute “costs”,13 this study showed its irrelevance for 
inclusion in the DCE. This may be explained by the fact 
that, in the Netherlands, DMARD therapy is covered by 
health insurance. There are no out-of-pocket costs involved 
for patients. Obviously, this attribute is context-specific and 
not easily generalizable.
It is clear that the included attributes are important to 
patients with RA in making choices regarding DMARD ther-
apy. Research has shown that there is an association between 
a decision making process in which healthcare providers take 
account of what is important to patients and higher treatment 
satisfaction.4,6 Treatment satisfaction in turn is associated 
with improved adherence.35 Patients are more likely to adhere 
to a treatment they are satisfied with. In clinical practice, 
it is therefore worthwhile paying attention to the included 
attributes when aiming to improve adherence. Healthcare 
providers should take them into account in the decision mak-
ing process. The DCE will eventually provide insight into the 
relative importance of the included attributes.
This study’s mixed-methods approach has been found 
highly suitable to identify, refine and select attributes and 
levels for a DCE. The benefits of several methods (ie, a lit-
erature review, expert recommendations, and focus groups) 
were utilized. A list of attributes and levels was derived 
from the literature review and expert recommendations. 
These two steps allowed a quick identification of attributes 
and levels. The list also proved to be comprehensive since 
only one new attribute was identified by the patients in the 
third focus group. It can therefore be argued that meanwhile 
there is sufficient literature available to identify attributes and 
levels of DMARDs, used to treat RA.
It is, however, crucial to use qualitative methods for 
the refinement and selection of attributes and levels. 
Qualitative analysis made it possible for the researchers 
to gain a deeper insight into the relevance of the attributes 
and levels from the view of patients with RA. Thus, the 
potential for misspecification through overreliance on the 
researchers’ own views was minimized. In this study, deci-
sions on the inclusion of attributes and levels were rooted 
in the patients’ voices (Table 4). Moreover, attributes and 
levels should be clearly described and explained where 
needed since they are frequently misunderstood.18 During 
the focus groups, the patients commented on the wording 
of the attributes and levels. This resulted in the inclusion of 
attributes and levels that are understandable to the DCE’s 
target group.
One of the challenges of selecting attributes and levels for 
inclusion is related to scaling down the often large number of 
attributes to a number manageable within a DCE. Although 
there is no fixed threshold number, the number of attributes 
is usually limited to ten.11,22 Beyond that, the choice tasks will 
get too complex. Hiligsmann et al used a nominal group tech-
nique to identify the most relevant attributes for inclusion.36 
They suggested that the use of a simple ranking exercise, 
such as the one in this study, may also be sufficient for this 
purpose. Abiiro et al also suggested to use simple quantitative 
tools for this purpose.37 However, they stated that qualitative 
reasoning would still be required to guarantee relevant attri-
butes and levels. Their statement was supported by this study. 
The attribute “frequency of administration”, for example, 
was not highly ranked. Nevertheless, it was included anyway 
based on the results of the qualitative analysis.
Several strengths and limitations of this study deserve 
attention. A strength was its mixed-methods approach. The 
methods that were used in this study have different pros 
and cons and complemented each other. The analysis of 
the qualitative data (ie, transcripts) was another strength. 
Researchers triangulation led to a broader and deeper under-
standing of the data. Moreover, bias was limited because of 
incorporating control on each other’s interpretations. The 
literature search was limited to the databases of PubMed, 
Embase and CINAHL. Relevant studies indexed only in 
other databases (eg, PsycINFO) may have been missed. 
However, this study has shown that the vast majority of 
attributes and levels were identified by the scoping review. It 
is unlikely that other studies, although relevant, would have 
resulted in the identification of new attributes and levels. 
Additionally, DMARDs not licensed in Europe at the time 
of the literature search, such as tofacitinib, were not included 
as search terms. This has not affected the validity of the 
results since studies investigating these DMARDs were still 
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found by other search terms. These DMARDs also do not 
have attributes and levels that differ from the ones that were 
identified in this study. When using qualitative methods, 
Coast et al recommended an iterative process between data 
collection and analysis.18 In this study, the data were col-
lected in advance and then analyzed. This was a limitation. 
However, it was checked whether data saturation occurred. 
If this had not been the case, additional focus groups would 
have been conducted. Another limitation is the convenience 
sampling approach that was used to recruit patients for the 
focus groups. According to Coast et al, the potential for 
misspecification of attributes and levels always exists, even 
when qualitative methods are used.18 It is therefore recom-
mended to use a purposive sampling approach in order to 
obtain a full range of views. Nevertheless, the patients in this 
study turned out to represent a mix of socio-demographic 
and clinical characteristics.
Conclusion
In this study, recently recommended methods to identify, 
refine, and select attributes and levels for a DCE were used 
and comprehensively described. Moreover, the suitability 
of a mixed-methods approach was highlighted. This study 
contributes to the limited literature on the development of 
attributes and levels for a DCE. Future research should pay 
more attention to a comprehensive description of this process. 
This ensures transparency and thereby allows researchers to 
judge a DCE’s quality and generalizability.
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Supplementary materials
(QJDJHPHQWTXHVWLRQV &RXOG\RXWHOOXVVRPHWKLQJDERXW\RXUVHOI" )RUH[DPSOHZKDW'0$5'VGR\RXFXUUHQWO\XVH"
7KLVTXHVWLRQZDVDVNHGWRWKHSDWLHQWVLQDURXQGURELQIDVKLRQ
([SORUDWRU\TXHVWLRQV 3DUW
7KHGHILQLWLRQRIDWWULEXWHVDQGOHYHOVLHZKDWDUHDWWULEXWHVDQGOHYHOV"ZDVH[SODLQHGWRWKHSDWLHQWV
:KDWDWWULEXWHVDQGOHYHOVDUHLPSRUWDQWWR\RXLQPDNLQJFKRLFHV UHJDUGLQJ'0$5'WKHUDS\":ULWHGRZQZKDWFRPHVWR\RXUPLQG
7KHSDWLHQWVFRXOGLQGLYLGXDOO\ZULWHGRZQWKHLUDQVZHUVRQDEODQNSDSHU
:KDWGLG\RXZULWHGRZQ"
7KLVTXHVWLRQZDVDVNHGWRWKHSDWLHQWVLQDURXQGURELQIDVKLRQ$OODQVZHUVZHUHZULWWHQRQDIOLSFKDUWE\WKHDVVLVWDQWPRGHUDWRU
:KDWDWWULEXWHVDQGOHYHOVDUHPRVWLPSRUWDQWWR\RX"3LFNWKUHHIURPWKHIOLSFKDUWDQGH[SODLQ\RXUFKRLFHV
7KLVTXHVWLRQZDVDVNHGWRWKHSDWLHQWVLQDURXQGURELQIDVKLRQ7KHSDWLHQWV¶FKRLFHVZHUHWDOOLHGRQWKHIOLSFKDUW
7DNHDORRNDWWKHIOLSFKDUW+DYH\RXPLVVHGDQ\WKLQJ"
3DUW
7KHOLVWZLWKFRQFHSWXDODWWULEXWHVDQGOHYHOVGHULYHGIURPWKHOLWHUDWXUHUHYLHZDQGH[SHUWUHFRPPHQGDWLRQVZDVSUHVHQWHGWRWKHSDWLHQWV
&RXOG\RXUDQNWKHDWWULEXWHVE\LPSRUWDQFH"
7KHSDWLHQWVFRXOGLQGLYLGXDOO\UDQNWKHDWWULEXWHVRQDZRUNVKHHW1HZO\LGHQWLILHGDWWULEXWHVFRXOGDOVREHUDQNHG
:KDWDUH\RXUKLJKHVWUDQNHGDWWULEXWHVSOHDVHH[SODLQ\RXUDQVZHU"
:KDWDUH\RXUORZHVWUDQNHGDWWULEXWHVSOHDVHH[SODLQ\RXUDQVZHU"
:KDWGR\RXWKLQNDERXWWKHZRUGLQJRIWKHDWWULEXWHVDQGOHYHOV"
([LWTXHVWLRQV ,VWKHUHDQ\WKLQJHOVH\RXZRXOGOLNHWRVKDUHZLWKXV"
Figure S1 Discussion guide.
Abbreviation: DMARD, disease-modifying antirheumatic drug.
±+RZORQJGLGLWWDNH\RXWRFRPSOHWHWKHVXUYH\"±:KDWGR\RXWKLQNDERXWWKHOHQJWKRIWKHVXUYH\"±+RZGLIILFXOWZDVLWIRU\RXWRFRPSOHWHWKHVXUYH\"±$UHWKHTXHVWLRQVLQWKHVXUYH\ZHOOH[SODLQHGSOHDVHH[SODLQ\RXUDQVZHU"±+DYH\RXPLVVHGDQ\WKLQJLQWKHVXUYH\"±'R\RXKDYHDQ\VXJJHVWLRQVDERXWKRZWRLPSURYHWKHVXUYH\"
Box S1 Open-ended questionnaire.
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 p
at
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at
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ra
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at
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 d
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 p
at
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 p
at
ie
nt
s 
ou
t 
of
 1
00
)
– 
se
ri
ou
s 
in
fe
ct
io
ns
 (
1 
pa
tie
nt
 o
ut
 
of
 1
00
, 5
 p
at
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 p
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 m
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 d
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 c
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ad
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at
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at
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at
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 p
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f p
at
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ra
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 b
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 b
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at
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 m
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at
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Developing attributes and levels for a discrete choice experiment
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at
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at
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at
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 p
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 c
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 b
la
ck
 a
nd
 
w
hi
te
 r
A
 p
at
ie
nt
s 
di
ffe
r 
in
 h
ow
 
th
ey
 m
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 b
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re
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at
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 d
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 t
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at
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 p
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at
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 d
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 c
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ra
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3)
 d
is
ea
se
 d
ur
at
io
n 

2 
ye
ar
s; 
an
d 
4)
 a
ct
iv
e 
di
se
as
e 
w
ith
 
6/
66
 s
w
ol
le
n 
jo
in
ts
, 

6/
68
 t
en
de
r 
jo
in
ts
 a
nd
 e
ith
er
 
an
 e
ry
th
ro
cy
te
 s
ed
im
en
ta
tio
n 
ra
te
 (
es
r
) 

28
 m
m
/h
 o
r 
a 
vi
su
al
 a
na
lo
g 
sc
al
e 
(V
A
s)
 g
lo
ba
l 
he
al
th
 
20
 m
m
 (
on
 a
 s
ca
le
 o
f 
0–
10
0 
m
m
 w
he
re
 0
 =
 b
es
t 
an
d 
10
0 
= 
w
or
st
).
– 
sa
m
pl
e 
si
ze
: 4
40
 p
at
ie
nt
s.
– 
im
pr
ov
em
en
t 
ge
ne
ra
l h
ea
lth
 
(y
es
/n
o)
– 
A
cc
ep
ta
bl
e 
cu
rr
en
t 
st
at
e 
of
 
he
al
th
 (
ye
s/
no
)
– 
K
in
d 
of
 t
re
at
m
en
t 
(o
ne
 w
el
l 
kn
ow
n 
D
M
A
R
D
, a
 c
om
bi
na
tio
n 
of
 w
el
l-k
no
w
n 
D
M
A
r
D
s 
w
ith
ou
t 
Pr
ed
ni
so
ne
, a
 c
om
bi
na
tio
n 
of
 
w
el
l-k
no
w
n 
D
M
A
r
D
s 
w
ith
 
Pr
ed
ni
so
ne
, a
 c
om
bi
na
tio
n 
of
 
w
el
l-k
no
w
n 
D
M
A
r
D
s 
w
ith
 a
 n
ew
 
in
tr
av
en
ou
s 
dr
ug
 (
In
fli
xi
m
ab
))
– 
r
ap
id
 r
el
ie
f o
f s
ym
pt
om
s 
(y
es
/n
o)
– 
g
oi
ng
 t
o 
th
e 
ho
sp
ita
l f
or
 
in
tr
av
en
ou
s 
tr
ea
tm
en
t 
(y
es
/n
o)
T
he
 im
pl
em
en
ta
tio
n 
of
 n
ew
 
tr
ea
tm
en
t 
st
ra
te
gi
es
 fo
r 
pa
tie
nt
s 
w
ith
 r
A
 is
 p
ri
m
ar
ily
 b
as
ed
 o
n 
th
e 
co
m
pa
ri
so
n 
of
 t
re
at
m
en
t 
ef
fe
ct
s,
 
si
de
 e
ffe
ct
s 
an
d 
co
st
s.
 T
he
 n
eg
at
iv
e 
pe
rc
ep
tio
n 
of
 P
re
dn
is
on
e 
an
d 
th
e 
po
si
tiv
e 
pe
rc
ep
tio
n 
of
 In
fli
xi
m
ab
 a
re
 
un
m
is
ta
ka
bl
e.
h
az
le
w
oo
d 
et
 a
l15
– 
T
o 
qu
an
tif
y 
th
e 
pr
ef
er
en
ce
s 
of
 p
at
ie
nt
s 
w
ith
 e
ar
ly
 r
A
 w
ith
 
th
e 
be
ne
fit
s 
an
d 
ha
rm
s 
of
 
D
M
A
r
D
s.
– 
id
en
tif
y 
an
y 
su
bg
ro
up
s 
of
 p
at
ie
nt
s 
w
ith
 d
iff
er
en
t 
tr
ea
tm
en
t 
pr
ef
er
en
ce
s.
D
c
e
– 
c
on
se
cu
tiv
e 
pa
tie
nt
s 
w
ith
 e
ar
ly
 
r
A
 (

2 
ye
ar
s 
si
nc
e 
di
ag
no
si
s 
by
 
a 
rh
eu
m
at
ol
og
is
t)
 fr
om
 e
ar
ly
 r
A
 
cl
in
ic
s.
– 
sa
m
pl
e 
si
ze
: 1
52
 p
at
ie
nt
s.
– 
c
ha
nc
e 
of
 a
 m
aj
or
 s
ym
pt
om
 
im
pr
ov
em
en
t 
by
 6
 m
on
th
s 
(3
0 
of
 
10
0 
pe
op
le
, 5
0 
of
 1
00
 p
eo
pl
e,
 
70
 o
f 1
00
 p
eo
pl
e)
– 
c
ha
nc
e 
of
 s
er
io
us
 jo
in
t 
da
m
ag
e 
by
 1
0 
ye
ar
s 
(2
 o
f 
10
0 
pe
op
le
, 1
5 
of
 1
00
 p
eo
pl
e,
 
30
 o
f 1
00
 p
eo
pl
e)
– 
c
ha
nc
e 
of
 s
to
pp
in
g 
th
e 
m
ed
ic
at
io
n 
du
e 
to
 a
 s
id
e 
ef
fe
ct
 b
y 
6 
m
on
th
s 
(2
 o
f 1
00
 
pe
op
le
, 1
0 
of
 1
00
 p
eo
pl
e,
 2
0 
of
 
10
0 
pe
op
le
)
– 
h
ow
 y
ou
 t
ak
e 
th
e 
m
ed
ic
at
io
n(
s)
 
(o
ne
 m
ed
ic
at
io
n:
 d
ai
ly
 p
ill
s,
 o
ne
 
m
ed
ic
at
io
n:
 w
ee
kl
y 
ta
bl
et
s,
 o
ne
 
m
ed
ic
at
io
n:
 w
ee
kl
y 
in
je
ct
io
ns
, 
tw
o 
m
ed
ic
at
io
ns
: w
ee
kl
y 
ta
bl
et
s 
an
d 
da
ily
 t
ab
le
ts
 (
tw
o 
pi
lls
), 
tw
o 
m
ed
ic
at
io
ns
: w
ee
kl
y 
ta
bl
et
s 
an
d
O
n 
av
er
ag
e,
 p
at
ie
nt
s 
w
ith
 e
ar
ly
 R
A
 
w
er
e 
ri
sk
 t
ol
er
an
t, 
bu
t 
im
po
rt
an
t 
di
ffe
re
nc
es
 in
 p
re
fe
re
nc
es
 w
er
e 
id
en
tifi
ed
. I
n 
pa
rt
ic
ul
ar
, a
 s
ub
gr
ou
p 
of
 p
at
ie
nt
s 
m
ay
 p
re
fe
r 
to
 a
vo
id
 
tr
ea
tm
en
ts
 w
ith
 a
 p
os
si
bl
e 
in
cr
ea
se
d 
ri
sk
 o
f c
an
ce
r/
in
fe
ct
io
n 
if 
ot
he
r 
ef
fe
ct
iv
e 
op
tio
ns
 a
re
 a
va
ila
bl
e.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 2
2-
O
ct
-2
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8
Fo
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Developing attributes and levels for a discrete choice experiment
 
in
je
ct
io
n 
at
 h
om
e 
ev
er
y 
w
ee
k,
 
tw
o 
m
ed
ic
at
io
ns
: w
ee
kl
y 
ta
bl
et
s 
an
d 
in
tr
av
en
ou
s 
in
fu
si
on
 in
 a
 
cl
in
ic
 o
r 
ho
sp
ita
l e
ve
ry
 8
 w
ee
ks
, 
th
re
e 
m
ed
ic
at
io
ns
: w
ee
kl
y 
ta
bl
et
s 
an
d 
da
ily
 t
ab
le
ts
 (
si
x 
pi
lls
))
– 
Po
ss
ib
le
 r
ar
e 
lu
ng
 o
r 
liv
er
 
re
ac
tio
n 
(n
ee
d 
fo
r 
re
gu
la
r 
bl
oo
d 
w
or
k)
 (
ye
s/
no
)
– 
n
ee
d 
fo
r 
re
gu
la
r 
ey
e 
ex
am
s 
(y
es
/n
o)
– 
sm
al
l r
is
k 
of
 s
er
io
us
 in
fe
ct
io
ns
 
an
d 
po
ss
ib
le
 in
cr
ea
se
d 
ri
sk
 o
f 
ce
rt
ai
n 
ca
nc
er
s 
(y
es
/n
o)
– 
n
ee
d 
to
 li
m
it 
al
co
ho
l (
ye
s/
no
)
h
uy
nh
 e
t 
al
31
– 
T
o 
ex
am
in
e 
th
e 
pr
ef
er
en
ce
s 
of
 b
io
lo
gi
c-
na
ïv
e 
an
d 
no
n-
na
ïv
e 
r
A
 p
at
ie
nt
s 
fo
r 
th
e 
ro
ut
e 
an
d 
fr
eq
ue
nc
y 
of
 a
dm
in
is
tr
at
io
n 
of
 
bi
ol
og
ic
 a
ge
nt
s.
– 
T
o 
ev
al
ua
te
 t
he
 s
am
e 
pr
ef
er
en
ce
s 
of
 r
he
um
at
ol
og
y 
he
al
th
 p
ro
fe
ss
io
na
ls
 w
he
n 
co
ns
id
er
in
g 
th
ei
r 
ow
n 
ne
ed
 fo
r 
tr
ea
tm
en
t.
Q
ue
st
io
nn
ai
re
 
to
 in
te
rr
og
at
e 
pr
ef
er
en
ce
s 
an
d 
to
 
ju
st
ify
 t
he
se
 
pr
ef
er
en
ce
s
– 
in
cl
us
io
n 
cr
ite
ri
on
 b
io
lo
gi
c 
no
n-
na
ïv
e 
r
A
 p
at
ie
nt
s:
 t
re
at
ed
 
w
ith
 In
fli
xi
m
ab
, A
ba
ta
ce
pt
, o
r 
T
oc
ili
zu
m
ab
 (
in
tr
av
en
ou
sl
y 
ad
m
in
is
te
re
d)
, o
r 
Et
an
er
ce
pt
 o
r 
A
da
lim
um
ab
 (
su
bc
ut
an
eo
us
ly
 
ad
m
in
is
te
re
d)
 fo
r 
at
 le
as
t 
6 
m
on
th
s.
– 
in
cl
us
io
n 
cr
ite
ri
on
 b
io
lo
gi
c-
na
ïv
e 
r
A
 p
at
ie
nt
s:
 t
re
at
ed
 
w
ith
 s
yn
th
et
ic
 D
M
A
r
D
s 
(a
dm
in
is
te
re
d 
or
al
ly
) 
fo
r 
at
 le
as
t 
6 
m
on
th
s.
– 
ex
cl
us
io
n 
cr
ite
ri
on
: p
at
ie
nt
s 
tr
ea
te
d 
in
tr
av
en
ou
sl
y 
on
ce
 
a 
ye
ar
 (
w
ith
 r
itu
xi
m
ab
) 
or
 
su
bc
ut
an
eo
us
ly
 o
nc
e 
a 
m
on
th
 
(w
ith
 g
ol
im
um
ab
) 
as
 t
he
 n
um
be
r 
of
 p
at
ie
nt
s 
w
as
 c
on
si
de
re
d 
to
o 
lo
w
.
– 
sa
m
pl
e 
si
ze
: 1
07
 b
io
lo
gi
c 
no
n-
na
ïv
e 
r
A
 p
at
ie
nt
s 
an
d 
 
35
 b
io
lo
gi
c-
na
ïv
e 
R
A
 p
at
ie
nt
s,
 
30
 r
he
um
at
ol
og
y 
he
al
th
 
pr
of
es
si
on
al
s.
– 
r
ou
te
 a
nd
 fr
eq
ue
nc
y 
of
 
ad
m
in
is
tr
at
io
n 
(in
tr
av
en
ou
s 
in
fu
si
on
 a
t 
th
e 
ou
tp
at
ie
nt
 c
lin
ic
 
(I
V
C
) 
ev
er
y 
8 
w
ee
ks
, I
V
C
 e
ve
ry
 
4 
w
ee
ks
, t
w
o 
IV
C
, t
w
o 
w
ee
ks
 
ap
ar
t, 
on
ce
 a
 y
ea
r,
 s
ub
cu
ta
ne
ou
s 
se
lf-
in
je
ct
io
n 
at
 h
om
e 
(s
c
h
) 
on
ce
 a
 w
ee
k,
 S
C
H
 e
ve
ry
 o
th
er
 
w
ee
k,
 S
C
H
 o
nc
e 
a 
m
on
th
, a
nd
 
sc
h
 w
ith
 t
he
 h
el
p 
of
 a
 h
om
e 
nu
rs
e 
on
ce
 a
 w
ee
k,
 e
ve
ry
 o
th
er
 
w
ee
k,
 o
r 
on
ce
 a
 m
on
th
)
– 
T
ra
ns
po
rt
at
io
n 
tim
e 
to
 t
he
 
ho
sp
ita
l
– 
ef
fe
ct
s
– 
A
dv
er
se
 e
ffe
ct
s
– 
Fi
na
nc
ia
l c
os
ts
T
he
 m
aj
or
ity
 o
f u
rb
an
 r
A
 
pa
tie
nt
s 
tr
ea
te
d 
w
ith
 b
io
lo
gi
cs
 
pr
ef
er
re
d 
th
ei
r 
cu
rr
en
t 
ro
ut
e 
of
 
ad
m
in
is
tr
at
io
n,
 b
ut
 r
ep
or
te
d 
a 
pr
ef
er
en
ce
 fo
r 
a 
lo
w
er
 t
re
at
m
en
t 
fr
eq
ue
nc
y.
 T
he
 m
aj
or
ity
 o
f u
rb
an
 
r
A
 p
at
ie
nt
s 
no
t 
cu
rr
en
tly
 t
re
at
ed
 
w
ith
 a
 b
io
lo
gi
c 
an
d 
th
e 
he
al
th
 
pr
of
es
si
on
al
s 
in
 r
he
um
at
ol
og
y 
fa
vo
re
d 
sc
h
 o
ve
r 
iV
c
 w
ith
 a
 lo
w
 
tr
ea
tm
en
t 
fr
eq
ue
nc
y.
 s
af
et
y 
is
su
es
 
w
er
e 
im
po
rt
an
t 
to
 p
at
ie
nt
s 
w
ho
 
pr
ef
er
re
d 
iV
c
.
(C
on
tin
ue
d)
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
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ov
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re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
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2-
O
ct
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8
Fo
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T
ab
le
 S
1 
(C
on
tin
ue
d)
P
ub
lic
at
io
n
O
bj
ec
ti
ve
(s
)
St
ud
y 
de
si
gn
St
ud
y 
po
pu
la
ti
on
 a
nd
 
sa
m
pl
e 
si
ze
A
tt
ri
bu
te
s 
(l
ev
el
s)
C
on
cl
us
io
n
li
si
ck
i a
nd
 c
hu
28
T
o 
id
en
tif
y 
th
e 
co
ns
id
er
at
io
ns
 
th
at
 a
re
 m
os
t 
im
po
rt
an
t 
to
 
pa
tie
nt
s 
an
d 
ph
ys
ic
ia
ns
 w
he
n 
de
ci
di
ng
 t
o 
in
iti
at
e 
bi
ol
og
ic
 
re
sp
on
se
 m
od
ifi
er
s 
(B
R
M
) 
th
er
ap
y 
fo
r 
r
A
.
O
nl
in
e 
su
rv
ey
– 
el
ig
ib
ili
ty
 c
ri
te
ri
a 
pa
tie
nt
s:
 
1)
 U
s 
re
si
de
nt
; 2
) 

18
 y
ea
rs
; 
3)
 p
hy
si
ci
an
-d
ia
gn
os
ed
 w
ith
 
m
od
er
at
e 
to
 s
ev
er
e 
r
A
; 
an
d 
4)
 t
ak
in
g 
qu
al
ifi
ed
 R
A
 
m
ed
ic
at
io
ns
 fo
r 

3 
m
on
th
s.
– 
Sa
m
pl
e 
si
ze
: 7
29
 p
at
ie
nt
s.
– 
sa
fe
ty
– 
Ef
fic
ac
y
– 
Ph
ys
ic
ia
n’
s 
ex
pe
ri
en
ce
 w
ith
 t
he
 
pr
od
uc
t
– 
M
et
ho
d 
of
 a
dm
in
is
tr
at
io
n
– 
D
os
in
g 
fr
eq
ue
nc
y 
(t
ie
d)
– 
Ph
ys
ic
ia
n’
s 
pe
rs
on
al
 p
re
fe
re
nc
e 
fo
r 
th
e 
pr
od
uc
t
– 
c
os
ts
– 
Y
ea
rs
 o
n 
th
e 
m
ar
ke
t
– 
Pa
tie
nt
 s
up
po
rt
 p
ro
gr
am
s
T
he
se
 d
at
a 
sh
ow
 t
ha
t 
ph
ys
ic
ia
ns
 
an
d 
pa
tie
nt
s 
sh
ar
e 
si
m
ila
r 
co
nc
er
ns
 
w
he
n 
de
ci
di
ng
 t
o 
in
iti
at
e 
Br
M
 
th
er
ap
y,
 a
lth
ou
gh
 p
at
ie
nt
s 
ra
nk
ed
 
sa
fe
ty
 a
s 
th
ei
r 
fir
st
 c
on
si
de
ra
tio
n,
 
w
he
re
as
 p
hy
si
ci
an
s 
ra
nk
ed
 e
ffi
ca
cy
 
fir
st
. T
he
re
fo
re
, p
at
ie
nt
 c
ou
ns
el
lin
g 
an
d 
ed
uc
at
io
n 
re
ga
rd
in
g 
ad
ve
rs
e 
ev
en
ts
 m
ay
 b
e 
he
lp
fu
l w
he
n 
re
co
m
m
en
di
ng
 B
r
M
 t
re
at
m
en
t.
lo
ud
er
 e
t 
al
33
T
o 
as
ce
rt
ai
n 
re
la
tiv
e 
pa
tie
nt
 
pr
ef
er
en
ce
s 
as
so
ci
at
ed
 w
ith
 
th
e 
ro
ut
e 
of
 a
dm
in
is
tr
at
io
n 
an
d 
ot
he
r 
at
tr
ib
ut
es
 o
f b
io
lo
gi
c 
D
M
A
r
D
s 
an
d 
ta
rg
et
ed
 s
yn
th
et
ic
 
D
M
A
r
D
s 
in
 t
he
 t
re
at
m
en
t 
of
 
pa
tie
nt
s 
w
ith
 r
A
.
c
ro
ss
-
se
ct
io
na
l 
po
st
al
 s
ur
ve
y,
 
us
in
g 
a 
co
m
pl
et
e 
bl
oo
d 
co
un
t 
(c
Bc
) 
an
al
ys
is
– 
in
cl
us
io
n 
cr
ite
ri
a:
 1
) 
ag
ed
 2
1 
to
 
80
 y
ea
rs
 a
t 
th
e 
tim
e 
of
 s
ur
ve
y 
ad
m
in
is
tr
at
io
n;
 a
nd
 2
) 
cu
rr
en
tly
 
en
ro
lle
d 
in
 a
 fu
lly
 in
su
re
d 
h
um
an
a 
co
m
m
er
ci
al
 h
ea
lth
 
pl
an
 w
ith
 m
ed
ic
al
 a
nd
 p
ha
rm
ac
y 
be
ne
fit
s 
an
d 
ha
ve
 h
ad
 a
t 
le
as
t 
2 
r
A
 r
el
at
ed
 m
ed
ic
al
 c
la
im
s 
in
 
th
e 
pr
ev
io
us
 1
2 
m
on
th
s,
 a
t 
le
as
t 
30
 d
ay
s 
ap
ar
t, 
as
 id
en
tifi
ed
 b
y 
In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 
D
is
ea
se
s,
 N
in
th
 R
ev
is
io
n,
 C
lin
ic
al
 
M
od
ifi
ca
tio
n 
di
ag
no
si
s 
co
de
 
71
4.
0 
(r
A
).
– 
ex
cl
us
io
n 
cr
ite
ri
a:
 1
) 
re
si
de
d 
in
 a
 n
ur
si
ng
 h
om
e;
 2
) 
el
ig
ib
le
 
fo
r 
lo
w
-in
-c
om
e 
su
bs
id
ie
s;
 
an
d 
3)
 e
vi
de
nc
e 
of
 a
 p
ai
d 
cl
ai
m
 fo
r 
T
of
ac
iti
ni
b 
or
 fo
r 
a 
bi
ol
og
ic
 D
M
A
r
D
 in
di
ca
te
d 
fo
r 
R
A
, p
so
ri
as
is
 o
r 
an
ky
lo
si
ng
 
sp
on
dy
lit
is
 (
A
s)
 a
t 
an
y 
tim
e 
du
ri
ng
 t
he
ir
 h
ea
lth
 p
la
n 
en
ro
llm
en
t 
be
fo
re
 t
he
 m
ai
lin
g 
of
 
th
e 
su
rv
ey
.
– 
sa
m
pl
e 
si
ze
: 3
80
 p
at
ie
nt
s.
– 
R
ou
te
 o
f a
dm
in
is
tr
at
io
n 
(o
ra
l, 
by
 
se
lf-
in
je
ct
io
n,
 b
y 
in
fu
si
on
)
– 
Fr
eq
ue
nc
y 
of
 a
dm
in
is
tr
at
io
n 
(t
w
ic
e 
da
ily
, o
nc
e 
w
ee
kl
y,
 e
ve
ry
 
ot
he
r 
w
ee
k,
 o
nc
e 
ev
er
y 
8 
w
ee
ks
)
– 
c
ha
nc
e 
of
 s
er
io
us
 s
id
e 
ef
fe
ct
s 
(4
 o
f 1
00
 p
eo
pl
e,
 6
 o
f 1
00
 
pe
op
le
, 8
 o
f 1
00
 p
eo
pl
e)
– 
M
on
th
ly
 c
os
ts
 t
o 
yo
u 
(c
om
m
er
ci
al
) 
($
25
 c
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Developing attributes and levels for a discrete choice experiment
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Developing attributes and levels for a discrete choice experiment
Table S2 Patients’ rankings of attributes during the focus groups
Ranking Attribute
1 risk of cancera
2 risk of liver injurya
3 Chance of efficacya
4 risk of joint damage
5 Onset of actiona
6 risk of serious infectionsa
7 Knowledge about long-term consequences of DMArD use
8 risk of gastrointestinal complications
9 route of administrationa
10 Years of experience with DMArD to treat rA
11 risk of mouth ulcers
12 risk of headache or dizziness
13 location of administration
14 Frequency of administrationa
15 combination therapy
16 risk of skin rash
17 Time needed for infusion
18 risk of hair loss
19 chance of injection side reaction
20 required storage conditions
21 Preparation of DMArD needed
22 costs
Notes: rank 1 means most relevant and rank 22 means least relevant. aThis attribute 
was eventually included in the Dce.
Abbreviations: RA, rheumatoid arthritis; DCE, discrete choice experiment; 
DMARD, disease-modifying antirheumatic drug.
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